Cagrilintide Phase 1 trial (NCT05564104)
A Study Investigating the Pharmacokinetic Properties of Cagrilintide in Participants With Various Degrees of Hepatic Impairment and Assessing the Absolute Bioavailability of Subcutaneous Cagrilintide in Healthy Volunteers
At a glance
- Phase
- Phase 1
- Status
- Completed
- Enrolment
- 32
- actual
- Start
- 5 Apr 2023 (actual)
- Primary completion
- 6 Sep 2024 (actual)
- Sponsor
- Novo Nordisk A/S
Arms and doses
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Part A: Participants with normal hepatic function | Experimental | Drug: Cagrilintide | Participants with normal hepatic function will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1. |
| Part A: Participants with mild hepatic impairment | Experimental | Drug: Cagrilintide | Participants with mild hepatic impairment (Child Pugh Grade A) will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1. |
| Part A: Participants with moderate hepatic impairment | Experimental | Drug: Cagrilintide | Participants with moderate hepatic impairment (Child-Pugh Grade B) will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1. |
| Part A: Participants with severe hepatic impairment | Experimental | Drug: Cagrilintide | Participants with severe hepatic impairment (Child-Pugh Grade C) will receive a single subcutaneous (s.c.) dose of 0.9 milligrams (mg) of cagrilintide on Day 1. |
| Part B: Sequence 1 | Experimental | Drug: Cagrilintide | Healthy participants will receive a single dose of cagrilintide Dose 1 intravenously (i.v) at the first dosing visit (Day 1), followed by a single dose of cagrilintide Dose 2 s.c. at the second dosing visit (Day 53). |
| Part B: Sequence 2 | Experimental | Drug: Cagrilintide | Healthy participants will receive a single dose of cagrilintide Dose 2 s.c. at the first dosing visit (Day 1), followed by a single dose of cagrilintide Dose 1 i.v at the second dosing visit (Day 53). |
Primary endpoint
| Measure | Time frame |
|---|---|
| Part A: AUC 0-infinity (∞), single dose (SD), cagri: The area under the cagrilintide plasma concentration-time curve fromtime 0 to infinity after a single dose | From 00 hours (pre-dose), 04, 08, 12, 18, 24, 30, 36, 48, 54, 60, 72, 84, 96, 120, 168, 336, 504, 672 to 840 hours (post dose) |
Key secondary endpoints
The first secondary outcomes listed on the registry record.
| Measure | Time frame |
|---|---|
| Part A: Cmax,SD,cagri: Maximum observed plasma cagrilintide concentration after a single dose | From 00 hours (pre-dose), 04, 08, 12, 18, 24, 30, 36, 48, 54, 60, 72, 84, 96 to 120 hours (post dose) |
| Part A: Tmax,SD,cagri: Time to maximum observed plasma cagrilintide concentration after a single dose | From 00 hours (pre-dose), 04, 08, 12, 18, 24, 30, 36, 48, 54, 60, 72, 84, 96 to 120 hours (post dose) |
| Part A: T½ SD,cagri:Terminal half-life for cagrilintide after a single dose | From 00 hours (pre-dose), 04, 08, 12, 18, 24, 30, 36, 48, 54, 60, 72, 84, 96, 120, 168, 336, 504, 672 to 840 hours (post dose) |
| Part A: CL/F SD,cagri:Apparent clearance of cagrilintide after a single dose | From 00 hours (pre-dose), 04, 08, 12, 18, 24, 30, 36, 48, 54, 60, 72, 84, 96, 120, 168, 336, 504, 672 to 840 hours (post dose) |
| Part B: AUC0-∞,SD,cagri: The area under the cagrilintide plasma concentration-time curve from time 0 to infinity after a single dose | From 00 hours (pre-dose), 05 mins, 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 30 mins, 02, 02 hours 30 mins, 03, 04, 05, 06, 08, 10, 12, 16, 18, 20, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 120, 168, 336, 504, 672 to 912 hours (post dose) |
| Part B: AUC0-last,SD,cagri: The area under the cagrilintide plasma concentration-time curve from time 0 to last quantifiable observation | From 00 hours (pre-dose), 05 mins, 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 30 mins, 02, 02 hours 30 mins, 03, 04, 05, 06, 08, 10, 12, 16, 18, 20, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 120, 168, 336, 504, 672 to 912 hours (post dose) |
| Part B: Cmax,SD,cagri: Maximum observed plasma cagrilintide concentration after a single dose | From 00 hours (pre-dose), 05 mins, 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 30 mins, 02, 02 hours 30 mins, 03, 04, 05, 06, 08, 10, 12, 16, 18, 20, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96 to 120 hours (post dose) |
| Part B: tmax,SD,cagri: Time to maximum observed plasma cagrilintide concentration after a single dose | From 00 hours (pre-dose), 05 mins, 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 30 mins, 02, 02 hours 30 mins, 03, 04, 05, 06, 08, 10, 12, 16, 18, 20, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96 to 120 hours (post dose) |
| Part B: t½ SD,cagri: Terminal half-life for cagrilintide after a single dose | From 00 hours (pre-dose), 05 mins, 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 30 mins, 02, 02 hours 30 mins, 03, 04, 05, 06, 08, 10, 12, 16, 18, 20, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 120, 168, 336, 504, 672 to 912 hours (post dose) |
| Part B: CL/F SD,cagri: Apparent clearance of cagrilintide after a single s.c. dose | From 00 hours (pre-dose), 05 mins, 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 30 mins, 02, 02 hours 30 mins, 03, 04, 05, 06, 08, 10, 12, 16, 18, 20, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 120, 168, 336, 504, 672 to 912 hours (post dose) |
| Part B: CL SD,cagri: Apparent clearance of cagrilintide after a single i.v. dose | From 00 hours (pre-dose), 05 mins, 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 30 mins, 02, 02 hours 30 mins, 03, 04, 05, 06, 08, 10, 12, 16, 18, 20, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 120, 168, 336, 504, 672 to 912 hours (post dose) |
| Part B: V z/F,cagri: Volume of distribution of cagrilintide after a single s.c. dose | From 00 hours (pre-dose), 05 mins, 15 mins, 30 mins, 45 mins, 1 hour, 1 hour 30 mins, 02, 02 hours 30 mins, 03, 04, 05, 06, 08, 10, 12, 16, 18, 20, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 120, 168, 336, 504, 672 to 912 hours (post dose) |
Who could enrol
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Results
No results posted on ClinicalTrials.gov as of 11 Oct 2026.
Hepatic impairment and a single cagrilintide dose
The registry title describes a single-dose cagrilintide study in people with reduced liver function and in healthy volunteers.[1]
Against normal liver function, mean AUC ratios were 0.99, 1.01 and 1.11 for mild, moderate and severe hepatic impairment.[2]
In both impairment studies, no serious treatment-emergent adverse events, withdrawals due to such events, or deaths were reported.[2]
The authors saw no rise in adverse events as renal or hepatic impairment increased.[2]
Sources
- 1A Study Investigating the Pharmacokinetic Properties of Cagrilintide in Participants With Various Degrees of Hepatic Impairment and Assessing the Absolute Bioavailability of Subcutaneous Cagrilintide in Healthy VolunteersClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 11 Oct 2026
- 2Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Clinical pharmacokinetics · 2026PMID 42228334Accessed 2 Oct 2026
Found an error? Report a correction.